TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy
Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.
Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?
Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.
Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs
CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.